Clinical and Molecular Pharmacologist Prof. Raymond Tjandrawinata of Dexa Group and Unika Atma Jaya, who also pioneers the development of Indonesia Indigenous Modern Medicine (OMAI), has achieved third place among the top pharmaceutical scientists in Indonesia. The AD Scientific Index provided this ranking based on a system that analyzes scientific performance and the added value of scientific productivity of each scientist.

“I thank God and am grateful for the support from friends and colleagues that have helped me achieve the rank of the third Best Scientist in Indonesia for the category of Pharmacy and Pharmaceutical Sciences, and also place in the top 3% in Indonesia for the category of Medical and Health Sciences, including publication citations,” Prof. Raymond stated, who also holds the position of Director of Research and Business Development at Dexa Group.

The AD Scientific Index cites Prof. Raymond’s article “Industry 4.0: This Century’s Industrial Revolution and Its Impact on Health and Biotechnology,” published in February 2016, as his most frequently referenced work. He remains active in writing scientific journals and opinion pieces for various national media outlets.

Annually, The AD Scientific Index updates and announces the world’s top scientists on its website. This year, it evaluated more than 1.6 million scientists from 23,242 institutions across 220 countries.

In Indonesia, Prof. Raymond ranks third in the pharmaceutical sector and eighteenth in the field of medicine and health. Researchers extensively reference his scientific works in pharmacy, medicine, and health.

Prof. Raymond also conducts extensive research and clinical trials of drugs both in Indonesia and internationally. His research products are marketed not only in Indonesia but abroad as well. Since 2005, he has been developing OMAI at Dexa Laboratories of Biomolecular Sciences (DLBS), and he has conducted significant research on chemically based medicines, earning 64 patents in Indonesia and internationally.

As a professor and researcher at the Faculty of Biotechnology at the Catholic University of Indonesia Atma Jaya, Prof. Raymond has explored science as far as the United States. Notably, his research reached outer space through the United States National Aeronautics and Space Administration (NASA).

In 1991, NASA astronaut Dr. Millie Hughes-Fulford invited Prof. Raymond to join the Spacelab Life Sciences (SLS 1) research project, which sent a shuttle to space to study osteoporosis in zero-gravity conditions among astronauts.

After studying as a Post Doctoral Fellow at the University of California, San Francisco, Prof. Raymond furthered his career in drug research using synthetic organic materials. He was one of the first Indonesians to have studied genetic engineering during the 1980s when the field was emerging in the United States and not yet fully explored in Indonesia.

In the early 2000s, Prof. Raymond returned to Indonesia to continue his career at a leading pharmaceutical company, PT Dexa Medica. The company’s founder, the late Rudy Soetikno, envisioned developing drugs from Indonesia’s natural wealth. In 2005, Prof. Raymond and the scientists at DLBS developed OMAI, which continues to this day. OMAI is a pharmaceutical product of Indonesian pride, boasting a Domestic Component Level (TKDN) above 80% and exported to 10 countries across three continents.dexagroup mpdf page 0001